Method of treating glaucoma
View Patent ↗Described are methods for the treatment of ocular hypertension or glaucoma comprising administering a pharmaceutically effective amount of one or more compounds that inhibit the enzyme EgLN-3. Certain embodiments of the invention combine the use of EgLN-3 with other glaucoma treatment agents. The compounds of the invention may be formulated in compositions comprising pharmaceutically acceptable carriers.
1. A method for the treatment of a patient with ocular hypertension or glaucoma, which comprises administering to said patient in an ophthalmic formulation a pharmaceutically effective amount of a compound that inhibits the enzyme EgLN-3, and wherein the compound is selected from the group consisting of:
wherein:
R is H, C 1-6 straight chain or branched alkyl, phenyl, or benzyl, or CO 2 R forms a salt of formula CO 2 − M + , with M + being Li + , Na + , K + , or NH 4 + ; and
R 1 is H, C(O)CH 3 , or C(O)C 6 H 5 .
2. The method of claim 1 , wherein the compound is selected from the group consisting of:
wherein:
R is H, H, CH 3 , C 2 H 5 , or i-C 3 H 7 ; and
R 1 is H or C(O)CH 3 .
3. The method of claim 1 , wherein the compound is administered in an implant.
4. The method of claim 1 , wherein the compound is administered as an intraocular injection.
5. The method of claim 1 wherein the compound is administered topically to the eye in a composition comprising a pharmaceutically acceptable carrier.
6. The method of claim 5 wherein the pharmaceutically effective amount of the compound in the composition is from 0.001 to 2% (w/v).
7. The method of claim 6 wherein the pharmaceutically effective amount is from 0.01 to 1% w/v).
8. The method of claim 5 , wherein the pharmaceutically acceptable carrier comprises one or more ingredients selected from the group consisting of surfactants; tonicity agents; buffers; preservatives; co-solvents; gelling agents, vehicles, water, penetration enhancers, and viscosity building agents.
9. The method of claim 1 wherein said administering further comprises administering said one or more compounds together with or separate from at least one glaucoma treatment agent selected from the group consisting of:
β-blockers, prostaglandin analogs, carbonic anhydrase inhibitors, α 2 agonists, miotics, rho kinase inhibitors and neuroprotectants.